Iterum Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ITRM research report →
Companywww.iterumtx.com
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
- CEO
- Corey N. Fishman
- IPO
- 2018
- Employees
- 9
- HQ
- Dublin, IE
Price Chart
Valuation
- Market Cap
- $1.60M
- P/E
- -0.03
- P/S
- 2.05
- P/B
- -0.09
- EV/EBITDA
- -1.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -171.28%
- Op Margin
- -5202.82%
- Net Margin
- -6913.08%
- ROE
- 602.38%
- ROIC
- -76.99%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-24,774,000 · 35.44%
- EPS
- $-1.26 · 57.43%
- Op Income
- $-18,696,000
- FCF YoY
- 31.95%
Performance & Tape
- 52W High
- $1.42
- 52W Low
- $0.03
- 50D MA
- $0.21
- 200D MA
- $0.52
- Beta
- 3.01
- Avg Volume
- 16.33M
Get TickerSpark's AI analysis on ITRM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ITRM Coverage
We haven't published any research on ITRM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ITRM Report →